newsfilter
← Latest News
Bloomberg·

MyoKardia Surges After Heart Drug Clears Late-Stage Hurdle

MyoKardia Inc. jumped on Monday after its experimental treatment for a rare heart condition met its primary goal and all secondary targets in a key study, delivering a win for the now $4.7 billion drugmaker.